Opthea Limited (AU:OPT)
ASX:OPT
Want to see AU:OPT full AI Analyst Report?
OPT Stock Chart & Stats
AU$0.60
-AU$0.04(-5.10%)
At close: 4:00 PM EST
AU$0.60
-AU$0.04(-5.10%)
Day’s Range― - ―
52-Week RangeAU$0.01 - AU$0.62
Previous CloseN/A
Volume897.04K
Average Volume (3M)0.00
Market Cap
AU$19.15M
Enterprise ValueAU$777.81M
Total Cash (Recent Filing)AU$48.22M
Total Debt (Recent Filing)AU$245.88M
Price to Earnings (P/E)―
Beta2.13
Next Earnings
Aug 28, 2026Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.14
Shares Outstanding1,367,978,100
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)-3.65
Price to Sales (P/S)29392.74
P/FCF Ratio-4.63
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)AU$200.00K
Bulls Say, Bears Say
Bulls Say
Focused Retinal PipelineOpthea's strategy centers on a clear clinical focus: a late-stage biologic (sozinibercept/OPT-302) designed to inhibit VEGF-C/D and used with anti-VEGF-A SOC for wet AMD and DME. That concentrated pipeline targets large, structural ophthalmic markets and creates a defined regulatory and commercial pathway if trials succeed.
Debt Eliminated In FY2025Eliminating debt materially reduces near-term leverage and interest obligations, lowering financial distress risk. For a cash-burning biotech this preserves optionality in financing choices, improves flexibility for partnering or milestone-based deals, and reduces insolvency risk versus leveraged peers.
Recent Positive Gross ProfitPositive gross profit in recent years suggests that direct program economics (e.g., collaborations, milestone/licensing revenue or early product-level margins) can be constructive. If commercial scale is reached, this implies potential for scalable margins before operating costs, supporting longer-term profitability prospects.
Bears Say
Persistent Heavy Cash BurnSustained ~-159M annual operating and free cash outflows indicate chronic cash consumption that materially shortens runway absent new funding or partnerships. This creates recurring dilution or financing risk and constrains long-term R&D plans and commercialization timing independent of clinical progress.
Negative Equity And Shrinking AssetsNegative shareholders' equity and a large decline in total assets reflect accumulated losses and a weakened capital base. This reduces balance sheet resilience, limits borrowing capacity, and raises the likelihood that future funding will require dilutive equity or onerous terms, impairing long-term strategic flexibility.
Minimal, Highly Volatile RevenueA dramatic ~92% revenue decline and consistently minimal top-line receipts mean the company lacks stable commercial cash generation. This makes operating continuity contingent on trial outcomes, milestone payments or capital markets, increasing execution risk and making sustainable margin improvement uncertain.
Opthea News
OPT FAQ
What was Opthea Limited’s price range in the past 12 months?
Opthea Limited lowest share price was AU$0.01 and its highest was AU$0.61 in the past 12 months.
What is Opthea Limited’s market cap?
Opthea Limited’s market cap is AU$19.15M.
When is Opthea Limited’s upcoming earnings report date?
Opthea Limited’s upcoming earnings report date is Aug 28, 2026 which is in 72 days.
How were Opthea Limited’s earnings last quarter?
Opthea Limited released its earnings results on Mar 01, 2026. The company reported AU$0.259 earnings per share for the quarter, beating the consensus estimate of N/A by AU$0.259.
Is Opthea Limited overvalued?
According to Wall Street analysts Opthea Limited’s price is currently Overvalued.
Does Opthea Limited pay dividends?
Opthea Limited does not currently pay dividends.
What is Opthea Limited’s EPS estimate?
Opthea Limited’s EPS estimate is 0.
How many shares outstanding does Opthea Limited have?
Opthea Limited has 1,367,978,100 shares outstanding.
What happened to Opthea Limited’s price movement after its last earnings report?
Opthea Limited reported an EPS of AU$0.259 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Opthea Limited?
Currently, no hedge funds are holding shares in AU:OPT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Opthea Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-20.45%
12-Months-Change
Fundamentals
Return on Equity
132.37%
Trailing 12-Months
Asset Growth
-83.74%
Trailing 12-Months
Company Description
Opthea Limited
Opthea Limited is an Australian clinical-stage biopharmaceutical company focused on developing and commercializing therapies primarily for eye diseases. The foundation of its development efforts lies in its intellectual property portfolio, which targets Vascular Endothelial Growth Factors (VEGF-C, VEGF-D, and VEGF Receptor-3). This technology is designed to address conditions linked to the growth of blood and lymphatic vessels, as well as vascular leakage. The company's leading asset, OPT 302, is a soluble form of VEGFR3 currently undergoing clinical trials. This novel therapy aims to treat wet neovascular age-related macular degeneration (wet AMD) and diabetic macular edema (DME). OPT 302 is distinguished as a first-in-class VEGF-C/D inhibitor, intended to be used in conjunction with VEGF-A inhibitors for the treatment of wet AMD and various other retinal diseases. Originally incorporated in 1984 as Circadian Technologies Limited, the company rebranded to Opthea Limited in December 2015 and is headquartered in South Yarra, Australia.
Technical Analysis
Cynata Therapeutics Limited
―
Mesoblast Limited
―
Telix Pharmaceuticals
―
Clarity Pharmaceuticals Ltd.
―
Recce Pharmaceuticals Ltd.
―
Options Prices
Currently, No data available
---